BD (Becton, Dickinson and Company) and Ypsomed recently expanded their collaboration to develop a 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe compatible with Ypsomed's YpsoMate 5.5 ...
BD and Ypsomed will expand their collaboration through the development of a 5.5 ml version of BD’s Neopak XtraFlow glass ...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the ...
TORONTO, April 8, 2025 /PRNewswire/ - AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced a new pipeline program in collaboration with a leading global ...
Although biologics are usually given by injection or intravenous infusion, oral formulations might be possible. In general, oral drugs offer many benefits, from simplified distribution to overall cost ...
Among patients with inflammatory bowel disease (IBD), overlapping biologic therapy was common during medication switches and was not associated with a higher risk for infection than nonoverlapping ...